Biogen Eyes Midyear BIIB080 Tau Data; SPINRAZA Uptake and SLE Trials On Tap
Biogen expects midyear BIIB080 proof-of-concept tau-lowering data following encouraging Phase 1b results and is evaluating various dosing regimens. High-dose SPINRAZA has launched in the US, Japan and Europe with strong uptake, and two Phase 3 SLE readouts for LITIFILIMAB are scheduled this year to inform filing decisions.
1. BIIB080 Tau-Lowering Program
Biogen’s BIIB080 is an antisense oligonucleotide designed to reduce tau protein levels. A Phase 1b trial showed meaningful tau reductions, prompting a midyear proof-of-concept study that will test multiple dosing regimens and assess cognitive outcomes.
2. SPINRAZA High-Dose Uptake
The high-dose formulation of SPINRAZA received approval in the US, Japan and Europe earlier this year. Patient uptake has been positive, bolstering revenue growth in the spinal muscular atrophy market.
3. LITIFILIMAB Phase 3 SLE Trials
Two Phase 3 trials of LITIFILIMAB in systemic lupus erythematosus are slated to read out later this year. Biogen will evaluate the totality of the data and may pursue regulatory filings based on a positive package read of both trials.
4. Alzheimer’s Biomarkers and SYFOVRE Position
Adoption of blood-based biomarkers for Alzheimer’s diagnosis is increasing, potentially accelerating LEQEMBI maintenance use and switches from Kisunla. SYFOVRE has demonstrated significant lesion growth reduction in geographic atrophy, with targeted ocular delivery enhancing its competitive positioning.